Cyril Amarchand Mangaldas advises sellers on INR 9,500 crore acquisition by Advent
Helen Saulnier
1 min read
Cyril Amarchand Mangaldas suggested the promoters of Suven Pharmaceuticals Limited (Suven Prescribed drugs) in relation to the acquisition of Suven Prescribed drugs by worldwide personal fairness firm Introduction, for an mixture amount of INR 9,500 crore (approx.) by means of a share purchase arrangement for c. 51% followed by an open up offer you for 26%.
The Normal Company and Competitors Legislation Practices of Cyril Amarchand Mangaldas acted as the authorized counsel for promoters of Suven Pharmaceuticals on the transaction. The scope of work provided enterprise seller due diligence workout, carrying out drafting, negotiations, evaluation and finalisation of the share acquire settlement and ancillary agreements. The transaction team was led by Shishir Vayttaden, Lover with aid from Reeti Agarwal, Affiliate Raksha Raina, Associate Kashish Mahajan, Associate Saumya Sharma, Associate and Tawishi Beria, Associate. Bhargav Joshi, Associate assisted with the due diligence training.
The Serious Estate crew was led by Namrata Kolar, Companion (Co-head-True Estate) with assistance from Jaideep Kodali, Principal Associate.
Pharma and Lifetime Sciences group was led by Biplab Lenin, Spouse with support from Kartik Jain, Senior Affiliate.
Avaantika Kakkar, Lover (Head-Competitors Regulation) advised on the opposition legislation related facets of the transaction.
As a element of the Transaction, Advent, has agreed to acquire out a vast majority in Suven Prescription drugs Minimal from our clients. Advent will also make an open offer to obtain 26% shares from public shareholders.
Other Get-togethers and Advisors to the transaction included Barclays (acted as banker for the sellers).
The transaction was signed on 26th December 2022.
